|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6630455B1
(en)
|
1995-01-13 |
2003-10-07 |
Vanderbilt University |
Methods for inducing mucosal immune responses
|
|
US6008202A
(en)
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
|
US7422902B1
(en)
*
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
WO1997004748A2
(en)
*
|
1995-08-01 |
1997-02-13 |
Advanced Therapies, Inc. |
Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
|
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
|
DE69629202T2
(de)
*
|
1995-10-18 |
2004-04-22 |
Vanderbilt University, Nashville |
Induktion von immunantworten der schleimhäute durch verabreichung von vitamine d3 und dns, die für ein antigen kodiert und die mit mit einem kationischen lipid ein complex bildet.
|
|
US7253731B2
(en)
|
2001-01-23 |
2007-08-07 |
Raymond Anthony Joao |
Apparatus and method for providing shipment information
|
|
US10011247B2
(en)
|
1996-03-27 |
2018-07-03 |
Gtj Ventures, Llc |
Control, monitoring and/or security apparatus and method
|
|
US10152876B2
(en)
|
1996-03-27 |
2018-12-11 |
Gtj Ventures, Llc |
Control, monitoring, and/or security apparatus and method
|
|
US7277010B2
(en)
|
1996-03-27 |
2007-10-02 |
Raymond Anthony Joao |
Monitoring apparatus and method
|
|
US6093816A
(en)
*
|
1996-06-27 |
2000-07-25 |
Isis Pharmaceuticals, Inc. |
Cationic lipids
|
|
US7309692B1
(en)
*
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
|
DE69725877T2
(de)
*
|
1996-08-26 |
2004-07-22 |
Transgene S.A. |
Kationische lipid-nukleinsäure komplexe
|
|
ES2187812T3
(es)
*
|
1996-09-13 |
2003-06-16 |
Lipoxen Technologies Ltd |
Composicion de liposomas.
|
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US6884430B1
(en)
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
|
WO1998051278A2
(en)
*
|
1997-05-14 |
1998-11-19 |
Inex Pharmaceuticals Corporation |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
|
EP2113247A3
(de)
|
1997-05-14 |
2010-05-05 |
The University Of British Columbia |
Hochwirksame Verkapselung von Nukleinsäuren in Lipidvesikeln
|
|
EP1017365B1
(de)
*
|
1997-06-23 |
2003-12-10 |
Sequus Pharmaceuticals, Inc. |
Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
|
|
US6110745A
(en)
*
|
1997-07-24 |
2000-08-29 |
Inex Pharmaceuticals Corp. |
Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
|
|
EP0998306A1
(de)
*
|
1997-07-24 |
2000-05-10 |
Inex Pharmaceuticals Corp. |
Liposomzusammensetzung für die verabreichung von nukleinsäure katalysator
|
|
US7704962B1
(en)
*
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US6734171B1
(en)
*
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
|
CA2792406A1
(en)
*
|
1997-10-10 |
1999-04-22 |
Tekmira Pharmaceuticals Corporation |
Methods for encapsulating nucleic acids in lipid bilayers
|
|
US6387695B1
(en)
*
|
1997-12-23 |
2002-05-14 |
Merck & Co., Inc. |
DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
|
|
ATE366121T1
(de)
*
|
1998-02-03 |
2007-07-15 |
Protiva Biotherapeutics Inc |
Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
|
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
US9075136B1
(en)
|
1998-03-04 |
2015-07-07 |
Gtj Ventures, Llc |
Vehicle operator and/or occupant information apparatus and method
|
|
US6841537B1
(en)
|
1998-04-22 |
2005-01-11 |
Protiva Biotherapeutics Inc. |
Combination therapy using nucleic acids and conventional drugs
|
|
US6841538B1
(en)
|
1998-04-22 |
2005-01-11 |
Inex Pharmaceuticals Corporation |
Combination therapy using nucleic acids and radio therapy
|
|
US7244714B1
(en)
*
|
1998-06-12 |
2007-07-17 |
Aradigm Corporation |
Methods of delivering aerosolized polynucleotides to the respiratory tract
|
|
WO1999065461A2
(en)
*
|
1998-06-19 |
1999-12-23 |
Genzyme Corporation |
Cationic amphiphile micellar complexes
|
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
|
US6667176B1
(en)
|
2000-01-11 |
2003-12-23 |
Geron Corporation |
cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
|
|
PT1129064E
(pt)
|
1998-11-12 |
2008-01-31 |
Invitrogen Corp |
Reagentes de transfecção
|
|
US6903077B1
(en)
*
|
1999-01-04 |
2005-06-07 |
University Of Vermont And State Agricultural College |
Methods and products for delivering nucleic acids
|
|
DE60012711T2
(de)
*
|
1999-03-26 |
2005-08-18 |
Vical, Inc., San Diego |
Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
|
|
US7311924B2
(en)
*
|
1999-04-01 |
2007-12-25 |
Hana Biosciences, Inc. |
Compositions and methods for treating cancer
|
|
US6852334B1
(en)
*
|
1999-04-20 |
2005-02-08 |
The University Of British Columbia |
Cationic peg-lipids and methods of use
|
|
US7094423B1
(en)
*
|
1999-07-15 |
2006-08-22 |
Inex Pharmaceuticals Corp. |
Methods for preparation of lipid-encapsulated therapeutic agents
|
|
EP1209971A4
(de)
*
|
1999-08-20 |
2004-04-14 |
Mirus Corp |
Ladungswechsel von polyion-komplexen
|
|
US20050249794A1
(en)
*
|
1999-08-27 |
2005-11-10 |
Semple Sean C |
Compositions for stimulating cytokine secretion and inducing an immune response
|
|
DE19944262A1
(de)
*
|
1999-09-15 |
2001-03-29 |
Cardiogene Gentherapeutische S |
Pharmazeutische Zusammensetzung in Form eines Nukleinsäure-Lipid-Komplexes, ihre Herstellung und Verwendung in der Gentherapie
|
|
EP1235842A4
(de)
*
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz
|
|
US6458382B1
(en)
*
|
1999-11-12 |
2002-10-01 |
Mirus Corporation |
Nucleic acid transfer complexes
|
|
AU2001237050A1
(en)
*
|
2000-02-17 |
2001-08-27 |
Genzyme Corporation |
Genetic modification of the lung as a portal for gene delivery
|
|
US20060127466A1
(en)
*
|
2000-02-25 |
2006-06-15 |
Arindam Sen |
Method for transdermal or intradermal delivery of molecules
|
|
CA2394088A1
(en)
*
|
2000-02-25 |
2001-08-30 |
Health Research, Inc. |
Method for transdermal or intradermal delivery of molecules
|
|
EP1133994A1
(de)
*
|
2000-03-11 |
2001-09-19 |
Biognostik Gesellschaft für biomolekulare Diagnostik mbH |
Verfahren zür Umwandlung des immunosuppresive effekts von MIA (Melanoma Inhibitory Activity)
|
|
EP1309726B2
(de)
|
2000-03-30 |
2018-10-03 |
Whitehead Institute For Biomedical Research |
Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
WO2001080900A2
(en)
*
|
2000-04-20 |
2001-11-01 |
The University Of British Columbia |
Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
|
|
US7452550B2
(en)
*
|
2000-06-30 |
2008-11-18 |
Hana Biosciences, Inc. |
Liposomal antineoplastic drugs and uses thereof
|
|
AU2001270413A1
(en)
*
|
2000-06-30 |
2002-01-14 |
Inex Pharmaceuticals Corporation |
Improved liposomal camptothecins and uses thereof
|
|
WO2002028367A1
(fr)
|
2000-10-04 |
2002-04-11 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de revetement de particules fines avec un film de lipides
|
|
JP2004521614A
(ja)
*
|
2000-10-27 |
2004-07-22 |
インヴィトロジェン コーポレーション |
アンチセンスオリゴヌクレオチドを真核細胞に導入する方法
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US20110301569A1
(en)
|
2001-01-20 |
2011-12-08 |
Gordon Wayne Dyer |
Methods and apparatus for the CVCS
|
|
AU2002256398A2
(en)
*
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
|
WO2002087541A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
|
US20030059899A1
(en)
*
|
2001-09-26 |
2003-03-27 |
Murali Sastry |
Method for the hydrophobisation of DNA molecules
|
|
AU2002340662B2
(en)
*
|
2001-11-07 |
2008-07-03 |
Tekmira Pharmaceuticals Corporation |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
|
US7223887B2
(en)
*
|
2001-12-18 |
2007-05-29 |
The University Of British Columbia |
Multivalent cationic lipids and methods of using same in the production of lipid particles
|
|
US20040043950A1
(en)
*
|
2002-01-03 |
2004-03-04 |
Board Of Regents, The University Of Texas System |
WT1 antisense oligos for the inhibition of breast cancer
|
|
EP1466133B1
(de)
|
2002-01-17 |
2007-01-03 |
York Refrigeration APS |
Getauchter verdampfer mit integriertem wärmeaustauscher
|
|
US10562492B2
(en)
|
2002-05-01 |
2020-02-18 |
Gtj Ventures, Llc |
Control, monitoring and/or security apparatus and method
|
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
|
EP1509203B1
(de)
*
|
2002-05-15 |
2016-04-13 |
California Pacific Medical Center |
Zuführung nukleinsäureähnlicher verbindungen
|
|
WO2003106636A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Mirus Corporation |
Novel methods for the delivery of polynucleotides to cells
|
|
WO2004002453A1
(en)
*
|
2002-06-28 |
2004-01-08 |
Protiva Biotherapeutics Ltd. |
Method and apparatus for producing liposomes
|
|
US20040151729A1
(en)
*
|
2002-10-28 |
2004-08-05 |
George Michalopoulos |
Novel long-term three-dimensional culture system
|
|
CA2506593C
(en)
*
|
2002-11-21 |
2012-02-07 |
Pevion Biotech Ltd. |
High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
|
|
AU2003302472B2
(en)
*
|
2002-11-22 |
2010-10-21 |
The Johns Hopkins University |
Target for therapy of cognitive impairment
|
|
AU2003300919A1
(en)
|
2002-12-11 |
2004-06-30 |
Coley Pharmaceutical Gmbh |
5' cpg nucleic acids and methods of use
|
|
JP2006524057A
(ja)
|
2003-04-21 |
2006-10-26 |
エペイウス バイオテクノロジーズ, インコーポレイテッド |
疾患を処置するための方法および組成物
|
|
US20070178066A1
(en)
*
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
AU2004247505B2
(en)
*
|
2003-06-18 |
2010-01-21 |
Biolab Ltd. |
Sphingolipids' polyalkylamines conjugates
|
|
US20050064595A1
(en)
|
2003-07-16 |
2005-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
WO2005021749A1
(en)
*
|
2003-08-28 |
2005-03-10 |
Novartis Ag |
Interfering rna duplex having blunt-ends and 3’-modifications
|
|
CA2551022C
(en)
*
|
2003-09-15 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
|
WO2005034979A2
(en)
*
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
|
EP2636739B1
(de)
|
2004-03-12 |
2014-12-10 |
Alnylam Pharmaceuticals Inc. |
iRNA-Wirkstoffe für VEGF-Targeting
|
|
CN102940891B
(zh)
|
2004-05-05 |
2016-02-24 |
赛伦斯治疗有限公司 |
脂质、脂质复合物及其应用
|
|
AU2005251691A1
(en)
*
|
2004-05-17 |
2005-12-22 |
Tekmira Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
|
CA2572450A1
(en)
|
2004-05-28 |
2005-12-15 |
Ambion, Inc. |
Methods and compositions involving microrna
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
EP1766035B1
(de)
*
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipidverkapselte interferenz-rna
|
|
AU2005259799A1
(en)
*
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory siRNA molecules and uses therefor
|
|
US20060051405A1
(en)
*
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
|
WO2006017476A2
(en)
*
|
2004-08-02 |
2006-02-16 |
The Research Foundation Of State University Of New York |
Amino functionalized ormosil nanoparticles as delivery vehicles
|
|
US20060045872A1
(en)
|
2004-08-25 |
2006-03-02 |
Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco |
Use of adipose tissue-derived stromal stem cells in treating fistula
|
|
AU2005304914B2
(en)
*
|
2004-11-05 |
2012-02-16 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
|
EP2281888B1
(de)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen, die miRNA und miRNA-inhibitorischen Molekülen verbunden sind
|
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
|
BRPI0519468A2
(pt)
*
|
2004-12-27 |
2009-01-27 |
Silence Therapeutics Ag |
complexos de lipÍdeos revestido e seu uso
|
|
EP2460875A1
(de)
|
2005-03-31 |
2012-06-06 |
Stemnion, Inc. |
Aus Amnion stammende Zellzusammensetzungen, Verfahren zur Herstellung und deren Verwendung
|
|
EP1736552A1
(de)
*
|
2005-06-22 |
2006-12-27 |
Universität Osnabrück |
Nukleolipide und deren Verwendung, sowie Vorrichtungen zur Nukleinsäureanalytik
|
|
CN103989633A
(zh)
|
2005-07-27 |
2014-08-20 |
普洛体维生物治疗公司 |
制造脂质体的系统和方法
|
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
|
WO2007048046A2
(en)
*
|
2005-10-20 |
2007-04-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of filovirus gene expression
|
|
WO2007051303A1
(en)
*
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
|
WO2007062399A2
(en)
|
2005-11-23 |
2007-05-31 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
|
WO2007119892A1
(en)
*
|
2006-04-17 |
2007-10-25 |
Chabiotech Co., Ltd. |
Methods for vitrification of human oocytes
|
|
AU2013257401B2
(en)
*
|
2006-04-20 |
2016-03-17 |
Silence Therapeutics Gmbh |
Lipoplex formulations for specific delivery to vascular endothelium
|
|
WO2007121947A1
(en)
*
|
2006-04-20 |
2007-11-01 |
Silence Therapeutics Ag. |
Lipoplex formulations for specific delivery to vascular endothelium
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
EP2584047B1
(de)
|
2006-05-11 |
2014-11-19 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der PCSK9-Genexpression
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
US20080213349A1
(en)
*
|
2006-09-11 |
2008-09-04 |
Deepak Ramesh Thakker |
Liposome Complexes Containing Pharmaceutical Agents and Methods
|
|
EP2076599A2
(de)
*
|
2006-09-19 |
2009-07-08 |
Asuragen, Inc. |
Mir-200-regulierte gene und wege als ziele für einen therapeutischen eingriff
|
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
|
US8221741B2
(en)
|
2007-01-17 |
2012-07-17 |
Marshall Vivienne S |
Methods for modulating inflammatory and/or immune responses
|
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
|
CN101688206B
(zh)
|
2007-07-05 |
2013-05-15 |
诺瓦提斯公司 |
用于治疗病毒感染的dsRNA
|
|
WO2009021325A1
(en)
|
2007-08-10 |
2009-02-19 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
|
EP2197495A2
(de)
*
|
2007-10-02 |
2010-06-23 |
MDRNA, Inc. |
Lipopeptide zur freisetzung von nukleinsäuren
|
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
|
CA2703852A1
(en)
*
|
2007-11-09 |
2009-05-14 |
Northeastern University |
Self-assembling micelle-like nanoparticles for systemic gene delivery
|
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
|
CA2930393C
(en)
|
2007-12-04 |
2022-11-29 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
AU2008335202A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor VII gene
|
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
EP3100718B1
(de)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
|
JP5697993B2
(ja)
|
2008-02-11 |
2015-04-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
修飾RNAiポリヌクレオチドおよびその使用
|
|
KR101397407B1
(ko)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
HUE034483T2
(en)
|
2008-04-15 |
2018-02-28 |
Protiva Biotherapeutics Inc |
New lipid preparations for introducing a nucleic acid
|
|
AU2009236219B8
(en)
|
2008-04-15 |
2015-06-25 |
Arbutus Biopharma Corporation |
Silencing of CSN5 gene expression using interfering RNA
|
|
EP2285960B1
(de)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-184modulation von neovaskularisation oder angiogenese
|
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
|
WO2010028054A1
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Europe Ag. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
|
JP2012502991A
(ja)
|
2008-09-22 |
2012-02-02 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚適用におけるrna干渉
|
|
AU2009296395A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
BRPI0920171A2
(pt)
*
|
2008-10-16 |
2016-07-12 |
Marina Biotech Inc |
processos e composições para liberação lipossômica e eficiente de terapêuticos de silenciamento de gene.
|
|
IL302142B2
(en)
|
2008-10-20 |
2024-07-01 |
Alnylam Pharmaceuticals Inc |
Compounds and methods for inhibiting transthyretin expression
|
|
WO2010062697A2
(en)
|
2008-10-30 |
2010-06-03 |
Peixuan Guo |
Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
|
|
CA3033577A1
(en)
|
2008-11-10 |
2010-05-14 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
WO2010088537A2
(en)
|
2009-01-29 |
2010-08-05 |
Alnylam Pharmaceuticals, Inc. |
Improved lipid formulation
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
|
CA2754043A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
WO2010107955A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
|
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP2411516A1
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von ask1 (apoptose-signalregulierende kinase 1) unter verwendung von sina (short interfering nucleic acid)
|
|
EP2411520A2
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
|
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
JP2012521762A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害
|
|
MX2011010072A
(es)
|
2009-03-27 |
2011-10-06 |
Merck Sharp & Dohme |
Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
|
|
WO2010129709A1
(en)
|
2009-05-05 |
2010-11-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid compositions
|
|
SMT201800499T1
(it)
|
2009-06-10 |
2018-11-09 |
Arbutus Biopharma Corp |
Formulazione lipidica migliorata
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
EP2449114B9
(de)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
EP2485768A1
(de)
|
2009-10-07 |
2012-08-15 |
Sanford-Burnham Medical Research Institute |
Verfahren und zusammensetzungen im zusammenhang mit an gerinnseln bindenden lipidzusammensetzungen
|
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
|
HUE038039T2
(hu)
|
2009-12-01 |
2018-09-28 |
Translate Bio Inc |
mRNS bejuttatása fehérjék és enzimek kiegészítésére humán genetikai betegségekben
|
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
|
WO2011075656A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
BR112012022570A2
(pt)
|
2010-03-08 |
2015-10-06 |
Monsato Technology Llc |
moléculas de polinucleotídeo para regulação de gene em plantas.
|
|
CN103200945B
(zh)
|
2010-03-24 |
2016-07-06 |
雷克西制药公司 |
眼部症候中的rna干扰
|
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
EP3560503B1
(de)
|
2010-03-24 |
2021-11-17 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei dermalen und fibrotischen erkrankungen
|
|
WO2011123468A1
(en)
|
2010-03-29 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Cd274/pd−l1遺伝子の発現を阻害するための組成物および方法
|
|
EP2382994A1
(de)
|
2010-04-26 |
2011-11-02 |
Maurizio Victor Cattaneo |
Durch Liganden gezielrichtete Nanokapseln zur Verabreichung von RNAi und anderen Wirkstoffen
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
US9944671B2
(en)
|
2010-06-02 |
2018-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
IL300109A
(en)
|
2010-06-03 |
2023-03-01 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the transfer of active substances
|
|
JP2013530187A
(ja)
|
2010-06-17 |
2013-07-25 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
炎症性疾患を治療するための組成物及び方法。
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
HRP20191232T1
(hr)
|
2010-08-17 |
2019-11-01 |
Sirna Therapeutics Inc |
Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
|
|
EP3372684B1
(de)
|
2010-08-24 |
2020-10-07 |
Sirna Therapeutics, Inc. |
Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
|
|
EP2609106A4
(de)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
Durch rna-interferenz vermittelte inhibition der prolyl-hydroxylase-domäne-2 (phd2)-genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
JP2013545453A
(ja)
|
2010-11-01 |
2013-12-26 |
ユニバーシティ・オブ・テクノロジー、シドニー |
免疫変調剤およびそれらの使用
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
EP2649182A4
(de)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
|
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
EP2663548B1
(de)
|
2011-01-11 |
2017-04-05 |
Alnylam Pharmaceuticals, Inc. |
Pegylierte lipide und ihre verwendung zur wirkstofffreisetzung
|
|
EP2670843B1
(de)
|
2011-02-03 |
2014-10-29 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Multivalente impfstoffe für tollwutvirus und filoviren
|
|
US9175290B2
(en)
|
2011-03-29 |
2015-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of TMPRSS6 gene
|
|
ME03491B
(de)
|
2011-06-08 |
2020-01-20 |
Translate Bio Inc |
Lipidnanoteilchenzusammensetzungen und verfahren zur mrna-freisetzung
|
|
EP4092120A1
(de)
|
2011-06-21 |
2022-11-23 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like-3 (anglptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
US9315813B2
(en)
|
2011-06-21 |
2016-04-19 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
EP3388068A1
(de)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
|
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
CN103957697B
(zh)
|
2011-09-13 |
2017-10-24 |
孟山都技术公司 |
用于杂草控制的方法和组合物
|
|
CA2848680C
(en)
|
2011-09-13 |
2020-05-19 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
US9840715B1
(en)
|
2011-09-13 |
2017-12-12 |
Monsanto Technology Llc |
Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
|
|
EP3434779A1
(de)
|
2011-09-13 |
2019-01-30 |
Monsanto Technology LLC |
Verfahren und zusammensetzungen zur unkrautbekämpfung
|
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
|
CA2848695A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and composition for weed control comprising inhibiting ppg oxidase
|
|
WO2013040057A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
US9920326B1
(en)
|
2011-09-14 |
2018-03-20 |
Monsanto Technology Llc |
Methods and compositions for increasing invertase activity in plants
|
|
US9701623B2
(en)
|
2011-09-27 |
2017-07-11 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
CA2853689C
(en)
|
2011-11-04 |
2020-06-30 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
|
EP3988537A1
(de)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
|
US9372831B2
(en)
|
2011-12-09 |
2016-06-21 |
Fujitsu Ten Limited |
Remote starter
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
EP3988104A1
(de)
|
2012-02-24 |
2022-04-27 |
Arbutus Biopharma Corporation |
Kationische trialkyllipide und verfahren zur verwendung davon
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
UY34822A
(es)
|
2012-05-24 |
2013-12-31 |
Seeds Ltd Ab |
Composiciones y métodos para silenciar la expresión genética
|
|
BR112014030677A2
(pt)
|
2012-06-08 |
2022-07-19 |
Shire Human Genetic Therapies |
distribuição pulmonar de mrna para células-alvo não-pulmonares
|
|
EP2859102A4
(de)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
Nukleaseresistente polynukleotide und verwendungen davon
|
|
JP6067315B2
(ja)
|
2012-10-12 |
2017-01-25 |
富士通テン株式会社 |
車両制御装置、及び、車両制御方法
|
|
BR112015008706A2
(pt)
|
2012-10-18 |
2018-02-06 |
Monsanto Technology Llc |
métodos e composições para controle de praga de plantas
|
|
EP3470061A1
(de)
|
2012-11-20 |
2019-04-17 |
Spectrum Pharmaceuticals, Inc. |
Verbessertes verfahren zur herstellung ein dosierung von in liposomen verkapseltem vincristin zur therapeutischen verwendung
|
|
EP3336187A1
(de)
|
2012-12-05 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
|
CN105358695B
(zh)
|
2013-01-01 |
2019-07-12 |
A.B.种子有限公司 |
将dsRNA引入植物种子以调节基因表达的方法
|
|
US10000767B2
(en)
|
2013-01-28 |
2018-06-19 |
Monsanto Technology Llc |
Methods and compositions for plant pest control
|
|
UA123082C2
(uk)
|
2013-03-13 |
2021-02-17 |
Монсанто Текнолоджи Ллс |
Спосіб та гербіцидна композиція для боротьби з видами рослин роду sorghum
|
|
US10612019B2
(en)
|
2013-03-13 |
2020-04-07 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
EP3467108B1
(de)
|
2013-03-14 |
2024-05-22 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
|
ES2882110T3
(es)
|
2013-03-14 |
2021-12-01 |
Translate Bio Inc |
Métodos y composiciones para administrar anticuerpos codificados con ARNm
|
|
US20140283211A1
(en)
|
2013-03-14 |
2014-09-18 |
Monsanto Technology Llc |
Methods and Compositions for Plant Pest Control
|
|
CA2902975C
(en)
|
2013-03-14 |
2021-05-11 |
Epeius Biotechnologies Corporation |
Thymidine kinase diagnostic assay for gene therapy applications
|
|
WO2014160129A2
(en)
|
2013-03-14 |
2014-10-02 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
EA037922B1
(ru)
|
2013-03-14 |
2021-06-07 |
Шир Хьюман Дженетик Терапис, Инк. |
мРНК CFTR И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА У МЛЕКОПИТАЮЩЕГО
|
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
|
EP3388834B1
(de)
|
2013-03-15 |
2020-04-15 |
Translate Bio, Inc. |
Synergistische verbesserung der abgabe von nukleinsäuren durch gemischte formulierungen
|
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
|
KR102049568B1
(ko)
|
2013-04-01 |
2019-11-27 |
삼성전자주식회사 |
히알루론산을 포함하는 핵산전달용 조성물
|
|
TW201515650A
(zh)
|
2013-05-06 |
2015-05-01 |
艾爾妮蘭製藥公司 |
遞送經脂質調配之核酸分子之劑量及方法
|
|
AU2014268529C1
(en)
|
2013-05-22 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
TMPRSS6 iRNA compositions and methods of use thereof
|
|
PT2999785T
(pt)
|
2013-05-22 |
2018-07-09 |
Alnylam Pharmaceuticals Inc |
Composições de irna de serpina1 e métodos de uso das mesmas
|
|
US10546441B2
(en)
|
2013-06-04 |
2020-01-28 |
Raymond Anthony Joao |
Control, monitoring, and/or security, apparatus and method for premises, vehicles, and/or articles
|
|
JP6412933B2
(ja)
|
2013-06-25 |
2018-10-24 |
ティジェニクス エス.エー.ユー. |
免疫調節活性を有する細胞集団、その調製方法および使用
|
|
US10077446B2
(en)
|
2013-06-25 |
2018-09-18 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Glucan-encapsulated siRNA for treating type 2 diabetes mellitus
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
JP6668236B2
(ja)
|
2013-07-19 |
2020-03-18 |
モンサント テクノロジー エルエルシー |
Leptinotarsa防除用組成物及びその方法
|
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
EP3052626A1
(de)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
|
JP6613227B2
(ja)
|
2013-10-04 |
2019-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Alas1遺伝子の発現を阻害する組成物および方法
|
|
EP3060258A1
(de)
|
2013-10-22 |
2016-08-31 |
Shire Human Genetic Therapies, Inc. |
Mrna-therapie für phenylketonurie
|
|
AU2014340092B2
(en)
|
2013-10-22 |
2019-09-19 |
Translate Bio, Inc. |
mRNA therapy for Argininosuccinate Synthetase Deficiency
|
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
|
EP3060671B1
(de)
|
2013-10-22 |
2021-12-29 |
Translate Bio, Inc. |
Bereitstellung von mrna ins zns und deren verwendung
|
|
WO2015066681A1
(en)
|
2013-11-04 |
2015-05-07 |
Monsanto Technology Llc |
Compositions and methods for controlling arthropod parasite and pest infestations
|
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
|
UA119253C2
(uk)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Спосіб боротьби із вірусом у кліща varroa та у бджіл
|
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
|
KR101713886B1
(ko)
|
2013-12-19 |
2017-03-10 |
연세대학교 산학협력단 |
PRK2를 표적으로 하는 C형 간염 바이러스 치료제 siRNA
|
|
AR099092A1
(es)
|
2014-01-15 |
2016-06-29 |
Monsanto Technology Llc |
Métodos y composiciones para el control de malezas utilizando polinucleótidos epsps
|
|
CN118845818A
(zh)
|
2014-02-11 |
2024-10-29 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
|
JP6606088B2
(ja)
|
2014-02-24 |
2019-11-13 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
|
|
CN106413390B
(zh)
|
2014-04-01 |
2019-09-27 |
孟山都技术公司 |
用于控制虫害的组合物和方法
|
|
EP3636742B1
(de)
|
2014-04-25 |
2025-11-05 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
CN112852809A
(zh)
|
2014-05-22 |
2021-05-28 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
|
CA2949106C
(en)
|
2014-05-30 |
2023-10-24 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
US10988764B2
(en)
|
2014-06-23 |
2021-04-27 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via RNA interference
|
|
EA033966B1
(ru)
|
2014-06-24 |
2019-12-13 |
Транслейт Био, Инк. |
Стереохимически обогащенные композиции для доставки нуклеиновых кислот
|
|
WO2015200539A1
(en)
|
2014-06-25 |
2015-12-30 |
Monsanto Technology Llc |
Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
|
|
CA3179824A1
(en)
|
2014-06-25 |
2015-12-30 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US9821738B2
(en)
|
2014-06-30 |
2017-11-21 |
Raymond Anthony Joao |
Battery power management apparatus and method
|
|
WO2016001846A1
(en)
|
2014-06-30 |
2016-01-07 |
Tigenix S.A.U. |
Mesenchymal stromal cells for treating sepsis
|
|
WO2016001845A1
(en)
|
2014-06-30 |
2016-01-07 |
Tigenix S.A.U. |
Mesenchymal stromal cells for treating rheumatoid arthritis
|
|
CN106456547B
(zh)
|
2014-07-02 |
2021-11-12 |
川斯勒佰尔公司 |
信使rna的包封
|
|
WO2016011203A1
(en)
|
2014-07-15 |
2016-01-21 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
|
US10378012B2
(en)
|
2014-07-29 |
2019-08-13 |
Monsanto Technology Llc |
Compositions and methods for controlling insect pests
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
|
CA2963271A1
(en)
|
2014-10-02 |
2016-04-07 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
|
ES2861597T3
(es)
|
2014-12-05 |
2021-10-06 |
Translate Bio Inc |
Terapia de ARN mensajero para el tratamiento de enfermedad articular
|
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
|
JP6942632B2
(ja)
|
2015-01-22 |
2021-09-29 |
モンサント テクノロジー エルエルシー |
Leptinotarsa防除用組成物及びその方法
|
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
AU2016233135B2
(en)
|
2015-03-19 |
2021-07-08 |
Translate Bio, Inc. |
mRNA therapy for pompe disease
|
|
AU2016237148A1
(en)
|
2015-03-24 |
2017-11-23 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
AU2016257996A1
(en)
|
2015-05-06 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA compositions and methods of use thereof
|
|
WO2016196738A1
(en)
|
2015-06-02 |
2016-12-08 |
Monsanto Technology Llc |
Compositions and methods for delivery of a polynucleotide into a plant
|
|
EP3302030A4
(de)
|
2015-06-03 |
2019-04-24 |
Monsanto Technology LLC |
Verfahren und zusammensetzungen zum einführen von nukleinsäuren in pflanzen
|
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
DK3313829T3
(da)
|
2015-06-29 |
2024-06-17 |
Acuitas Therapeutics Inc |
Lipider og lipide nanopartikelformuleringer til levering af nukleinsyrer
|
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
EP3329003A2
(de)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
CN114525280A
(zh)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
|
WO2017048843A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
AU2016338559B2
(en)
|
2015-10-14 |
2022-11-24 |
Translate Bio, Inc. |
Modification of RNA-related enzymes for enhanced production
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
ES2938557T3
(es)
|
2015-10-28 |
2023-04-12 |
Acuitas Therapeutics Inc |
Lípidos y formulaciones de nanopartículas lipídicas novedosos para la entrega de ácidos nucleicos
|
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
|
AU2017214761B2
(en)
|
2016-02-01 |
2024-02-01 |
Epiaxis Therapeutics Pty Ltd |
Proteinaceous compounds and uses therefor
|
|
EP3419635B1
(de)
|
2016-02-22 |
2022-01-05 |
Centauri Biotech, S.L. |
Pharmazeutische oder veterinärmedizinische zusammensetzungen mit mesenchymalen stromazellen (msc) und dimethylsulfoxid (dmso)
|
|
GB201604304D0
(en)
|
2016-03-14 |
2016-04-27 |
Tigenix S A U |
Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
|
|
EP4104854A3
(de)
|
2016-04-04 |
2023-03-08 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Multivalente impfstoffe gegen tollwutvirus und coronaviren
|
|
EP3440206B1
(de)
|
2016-04-08 |
2020-10-28 |
Translate Bio, Inc. |
Multimere codierende nukleinsäuren und verwendungen davon
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
EP3469074B1
(de)
|
2016-06-13 |
2020-12-09 |
Translate Bio, Inc. |
Messenger-rna-therapie zur behandlung von ornithintranscarbamylasemangel
|
|
JP7086870B2
(ja)
|
2016-06-30 |
2022-06-20 |
アルブータス・バイオファーマー・コーポレイション |
メッセンジャーrnaを送達するための組成物及び方法
|
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
TWI790217B
(zh)
|
2016-12-16 |
2023-01-21 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法
|
|
EP3585417B1
(de)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Methode der herstellung von codon-optimierter cftr-mrna
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
KR102720270B1
(ko)
|
2017-04-18 |
2024-10-23 |
알닐람 파마슈티칼스 인코포레이티드 |
B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법
|
|
WO2018195355A1
(en)
|
2017-04-19 |
2018-10-25 |
Rxi Pharmaceuticals Corporation |
Topical delivery of nucleic acid compounds
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
EP3621669B1
(de)
|
2017-05-11 |
2023-11-01 |
Tc1 Llc |
Thermische verbindung für implantierbare blutpumpe
|
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
JP7429536B2
(ja)
|
2017-08-04 |
2024-02-08 |
協和キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US12065396B2
(en)
|
2017-08-17 |
2024-08-20 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019053295A1
(en)
|
2017-09-18 |
2019-03-21 |
Fundació Institut D'investigació Sanitària Pere Virgili |
METHODS FOR IMPROVING THE EFFICACY OF CELL THERAPY WITH MESENCHYMAL STEM CELL POPULATIONS
|
|
EP3704252A1
(de)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
US20210371877A1
(en)
*
|
2017-12-18 |
2021-12-02 |
Spark Therapeutics, Inc. |
Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
|
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
JP7417529B2
(ja)
|
2018-03-07 |
2024-01-18 |
サノフイ |
ヌクレオチド前駆体、ヌクレオチド類似体およびこれを含むオリゴマー化合物
|
|
AR115960A1
(es)
|
2018-08-16 |
2021-03-17 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen lect2
|
|
CN118421617A
(zh)
|
2018-08-24 |
2024-08-02 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
EP3852911B1
(de)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
MX2021005969A
(es)
|
2018-11-21 |
2021-09-14 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
|
|
CN113166760A
(zh)
|
2018-11-23 |
2021-07-23 |
赛诺菲 |
用于抑制angptl8的新型rna组合物和方法
|
|
EP3887516A1
(de)
|
2018-11-29 |
2021-10-06 |
Flagship Pioneering Innovations V, Inc. |
Verfahren zur modulation von rna
|
|
EP3894559A4
(de)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
Verfahren zur behandlung von störungen der trinukleotid-repeat-expansion im zusammenhang mit mlh3-aktivität
|
|
US20220049252A1
(en)
|
2018-12-10 |
2022-02-17 |
Amgen Inc. |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
|
JP2022511550A
(ja)
|
2018-12-10 |
2022-01-31 |
アムジエン・インコーポレーテツド |
PNPLA3発現を阻害するためのRNAiコンストラクト
|
|
RS67553B1
(sr)
|
2018-12-20 |
2026-01-30 |
Humabs Biomed Sa |
Kombinovana hbv terapija
|
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
EP4450487A3
(de)
|
2019-01-11 |
2024-12-25 |
Acuitas Therapeutics, Inc. |
Lipide zur lipidnanopartikelfreisetzung von wirkstoffen
|
|
CN113924368B
(zh)
|
2019-05-30 |
2025-02-07 |
美国安进公司 |
用于抑制scap表达的rnai构建体及其使用方法
|
|
US12381953B2
(en)
|
2019-07-01 |
2025-08-05 |
Raymond Anthony Joao |
Control, monitoring, and/or security, apparatus and method for premises, vehicles, and/or articles
|
|
GB201910299D0
(en)
|
2019-07-18 |
2019-09-04 |
Aouadi Myriam |
Medical uses, methods and uses
|
|
EP4013870A1
(de)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
|
|
AU2020329286A1
(en)
|
2019-08-13 |
2022-03-17 |
Amgen Inc. |
RNAi constructs for inhibiting SLC30A8 expression and methods of use thereof
|
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
|
JP7805286B2
(ja)
|
2019-09-03 |
2026-01-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Lect2遺伝子の発現を阻害するための組成物および方法
|
|
WO2021044004A1
(en)
|
2019-09-05 |
2021-03-11 |
Sanofi |
Oligonucleotides containing nucleotide analogs
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
|
US12380294B2
(en)
|
2019-11-01 |
2025-08-05 |
Raymond Anthony Joao |
Control, monitoring, and/or security, apparatus and method for premises, vehicles, and/or articles
|
|
BR112022009598A2
(pt)
|
2019-11-18 |
2022-08-16 |
Janssen Biotech Inc |
Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
|
|
AU2020387478A1
(en)
*
|
2019-11-22 |
2022-06-16 |
Samyang Holdings Corporation |
Kit for preparing nanoparticle composition for drug delivery
|
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
|
AU2020399636A1
(en)
|
2019-12-09 |
2022-06-02 |
Amgen Inc. |
RNAi constructs and methods for inhibiting LPA expression
|
|
BR112022011417A2
(pt)
|
2019-12-13 |
2022-08-30 |
Alnylam Pharmaceuticals Inc |
Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
|
EP4121018A4
(de)
|
2020-03-17 |
2024-07-03 |
Genevant Sciences Gmbh |
Kationische lipide zur lipidnanopartikelabgabe von therapeutika an hepatische stellatzellen
|
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
コロナウイルスiRNA組成物およびその使用方法
|
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
WO2021202902A1
(en)
|
2020-04-01 |
2021-10-07 |
Alnylam Pharmaceuticals, Inc. |
ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AU2021252545A1
(en)
|
2020-04-06 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
KR20230008078A
(ko)
|
2020-04-07 |
2023-01-13 |
알닐람 파마슈티칼스 인코포레이티드 |
Scn9a 발현을 사일런싱하기 위한 조성물 및 방법
|
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
KR20230022415A
(ko)
|
2020-05-18 |
2023-02-15 |
맥스 바이올로지 컴퍼니 리미티드 |
지질-중합체 조성물 및 사용 방법
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
MX2022015169A
(es)
|
2020-06-01 |
2023-07-03 |
Amgen Inc |
Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
|
EP4649951A2
(de)
|
2020-06-09 |
2025-11-19 |
Alnylam Pharmaceuticals, Inc. |
Sirna-zusammensetzungen und verfahren zur ausschaltung von polyglycerol-3-phosphat-acyltransferase-1, mitochondrien)-expression
|
|
CN116390943A
(zh)
|
2020-06-24 |
2023-07-04 |
维尔生物科技有限公司 |
工程化乙型肝炎病毒中和抗体和其用途
|
|
EP4176087A1
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Verfahren zur bestimmung des ansprechens auf eine prostatakrebsbehandlung
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4175664A2
(de)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostata-neoantigene und ihre verwendungen
|
|
CA3177613A1
(en)
|
2020-07-10 |
2022-04-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
|
EP4182297B1
(de)
|
2020-07-16 |
2025-09-03 |
Acuitas Therapeutics, Inc. |
Kationische lipide zur verwendung in lipidnanopartikeln
|
|
US20220047621A1
(en)
|
2020-08-13 |
2022-02-17 |
Amgen Inc. |
RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION
|
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
|
WO2022074541A1
(en)
|
2020-10-05 |
2022-04-14 |
Max Biology Co. Ltd. |
Cannabinoid-containing compositions and use for treating and preventing diseases
|
|
EP4225330A1
(de)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230383294A1
(en)
|
2020-10-16 |
2023-11-30 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl3
|
|
US20240035029A1
(en)
|
2020-10-16 |
2024-02-01 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
|
JP2023546199A
(ja)
|
2020-10-20 |
2023-11-01 |
サノフイ |
アシアロ糖タンパク質受容体のための新規リガンド
|
|
WO2022087041A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
AU2021373780A1
(en)
|
2020-11-05 |
2023-06-08 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
AU2021385572A1
(en)
|
2020-11-25 |
2023-06-22 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
EP4256053A1
(de)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
|
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
CA3210763A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
US11760227B2
(en)
|
2021-02-15 |
2023-09-19 |
Raymond Anthony Joao |
Battery power management apparatus and method
|
|
WO2022182864A1
(en)
|
2021-02-25 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods and methods of use thereof
|
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
KR20240005692A
(ko)
*
|
2021-03-22 |
2024-01-12 |
리코드 테라퓨틱스, 인크. |
세포로의 표적화 전달을 위한 조성물 및 방법
|
|
CN117203336A
(zh)
|
2021-03-29 |
2023-12-08 |
阿尔尼拉姆医药品有限公司 |
亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法
|
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
EP4330396A1
(de)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
CN117561334A
(zh)
|
2021-06-04 |
2024-02-13 |
阿尔尼拉姆医药品有限公司 |
人染色体9开放阅读框72(C9ORF72)iRNA药剂组合物和其使用方法
|
|
WO2022269097A1
(en)
|
2021-06-25 |
2022-12-29 |
Alpine Antiviral Gmbh |
Sirna combinations targeting sars-cov-2 and/or host factor transcripts
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
US20250034564A1
(en)
|
2021-06-29 |
2025-01-30 |
Korro Bio, Inc. |
Methods and Compositions for ADAR-Mediated Editing
|
|
TW202325312A
(zh)
|
2021-07-23 |
2023-07-01 |
美商艾拉倫製藥股份有限公司 |
β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
IL311030A
(en)
|
2021-08-31 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
DFFA-like Cell Death Inducer B (CIDEB) IRNA compositions and methods of using them
|
|
KR20240067943A
(ko)
|
2021-09-24 |
2024-05-17 |
알닐람 파마슈티칼스 인코포레이티드 |
미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
|
|
JP2024537098A
(ja)
|
2021-10-05 |
2024-10-10 |
アムジエン・インコーポレーテツド |
オリゴヌクレオチド化合物の遺伝子サイレンシング活性を増強するための組成物及び方法
|
|
AU2022368907A1
(en)
|
2021-10-20 |
2024-05-02 |
University Of Copenhagen |
Rejuvenation treatment of age-related white matter loss
|
|
EP4419683A1
(de)
|
2021-10-22 |
2024-08-28 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur unterbrechung der nrf2-keap1-proteininteraktion durch adar-vermittelte rna-editierung
|
|
IL311839A
(en)
|
2021-10-22 |
2024-05-01 |
Amgen Inc |
RNA interference constructs to inhibit gpam expression and methods for using them
|
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
CN118647600A
(zh)
|
2021-12-16 |
2024-09-13 |
爱康泰生治疗公司 |
用于脂质纳米颗粒制剂的脂质
|
|
AU2022421244A1
(en)
|
2021-12-22 |
2024-07-11 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
AU2023210727A1
(en)
|
2022-01-25 |
2024-07-11 |
Albert-Ludwigs-Universität Freiburg |
A glun2d inhibitor for use in the treatment or relapse prevention of a depressive episode
|
|
EP4466250B1
(de)
|
2022-01-31 |
2025-03-26 |
Genevant Sciences Gmbh |
Ionisierbare kationische lipide für lipidnanopartikel
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
US12064479B2
(en)
|
2022-05-25 |
2024-08-20 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
AU2023283551A1
(en)
|
2022-06-10 |
2024-12-19 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
|
EP4562152A2
(de)
|
2022-07-25 |
2025-06-04 |
Amgen Inc. |
Rnai-konstrukte und verfahren zur hemmung der fam13a-expression
|
|
MA71735A
(fr)
|
2022-09-15 |
2025-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|
|
JP2025540101A
(ja)
|
2022-12-01 |
2025-12-11 |
キャンプ4 セラピューティクス コーポレイション |
調節rnaを標的とするアンチセンスオリゴヌクレオチドを用いたsyngap1遺伝子転写の調節
|
|
UY40566A
(es)
|
2022-12-16 |
2024-06-28 |
Amgen Inc |
Constructos de arni para inhibir la expresión de ttr y métodos de uso de los mismos
|
|
CN115624539A
(zh)
*
|
2022-12-16 |
2023-01-20 |
首都医科大学附属北京朝阳医院 |
一种脂质纳米颗粒及其制备方法和应用
|
|
EP4658294A2
(de)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Kompetitiver ersatz von gliazellen
|
|
WO2024168010A2
(en)
|
2023-02-09 |
2024-08-15 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015335A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|
|
US20250313840A1
(en)
|
2024-03-20 |
2025-10-09 |
Vertex Pharmaceuticals Incorporated |
Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
|
|
WO2025226980A2
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025255388A1
(en)
|
2024-06-05 |
2025-12-11 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026006275A2
(en)
|
2024-06-26 |
2026-01-02 |
Amgen Inc. |
Rnai constructs and methods for inhibiting expression of inhbe
|